Rahul Bhargava, Director and Head of Hematology, Hematocology, and Stem Cell Transplant at Fortis Health Care, shared a post on LinkedIn:
“Cartogene Therapeutics to bring CAR-T therapies to India-Establishes a facility with 700 patient annual capacity in Gurugram?
The start-up world is working to make CAR-T cells more affordable and accessible.
My quote:
India will need more such centres as CAR-T cells are slowly replacing bone marrow transplants for lymphomas and finding new indications each month, whether autoimmune disorders or solid tumours.
The future is bright.
Shrinidhi Nathany, Anusha S., DBT/WT India Alliance, DBT BIRAC, Indian Council of Medical Research (ICMR), Sumit Wadhwa and team, all the best.”
More posts featuring Rahul Bhargava on OncoDaily.